---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-087227"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:41:27.764640+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q2 net product rev $12.1M (+9% YoY); net loss $18.8M; FY guidance reaffirmed

## Summary
- DEXTENZA net product revenue $12.1M in Q2 2022, up 9% YoY from $11.1M; total net revenue $12.3M.
- Net loss $18.8M ($0.24 basic / $0.25 diluted EPS) vs $8.5M loss in Q2 2021.
- Reiterates FY2022 DEXTENZA net product revenue guidance of $55-60M (26%-38% growth).
- Cash and equivalents $134.5M at June 30, 2022; expects to fund operations through 2023.
- Interim OTX-TKI (wet AMD) Phase 1 data to be presented at AAO in September 2022.

## SEC filing metadata
- accession: 0001104659-22-087227
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465922087227/0001104659-22-087227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465922087227/tm2222774d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-087227
- JSON: https://secwatch.observer/filing/0001104659-22-087227.json
- Plain text: https://secwatch.observer/filing/0001104659-22-087227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.